Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Withdrawn before enrolling · Phase 2
Conditions studied: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
In brief
The purpose of this research study is to see if Eculizumab (Soliris®) can safely be used in addition to conventional therapy in patients with active ANCA (Antineutrophil Cytoplasmic Autoantibodies ) vasculitis and lead to a more rapid decrease in disease activity. ANCA vasculitis is an inflammation of the small vessels whereby ANCA antibodies inappropriately activate one's own white blood cells (neutrophils) and cause damage to the small blood vessels.
Key facts
- Study ID
- NCT01275287
- Run by
- University of North Carolina, Chapel Hill
- People needed
- 0
- Starts
- 2011-05-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2017-02-23
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UNC Kidney Center — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.